Sarah Mason

Cerebrovascular and blood–brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology

Janelle Drouin‐Ouellet, Stephen J. Sawiak, Giulia Cisbani et al. · Annals of Neurology · 2015 · 282 citations · Full text

Potential Implications, Neurochemical Biomarkers, Social Sciences +21

Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: A multimodal imaging study

Marios Politis, Nicola Pavese, Yen Tai et al. · Human Brain Mapping · 2010 · 206 citations · Full text

Neurochemical Biomarkers, Multimodal Imaging Study, Neuroinflammation +20

5‐Hydroxytryptamine (5‐HT)₄ receptors in <i>post mortem</i> human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases

Gavin P. Reynolds, Sarah Mason, A. Meldrum et al. · British Journal of Pharmacology · 1995 · 198 citations · Full text

Neurotransmitter, Hill Coefficients, Social Sciences +16

Health‐related quality of life in Huntington's disease: Which factors matter most?

Aileen K. Ho, A. Gilbert, Sarah Mason et al. · Movement Disorders · 2008 · 143 citations

Quality Of Life, Life Assessment, Neuropsychiatry +16

Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease

Stéphane Palfi, Jean Marc Gurruchaga, H. Lepetit et al. · Human Gene Therapy Clinical Development · 2018 · 137 citations · Full text

Phase I/ii Study, Dopamine Receptors, Pharmacotherapy +16